All News
#ACR BEST Abstracts from San Diego – Day 1
The RheumNow faculty reporters have been scouring the meeting for what they believe to be the best presentations from the first day at ACR 2023 in San Diego. From hundreds of online presentations, the poster floor and the plenary podium, here are some of the best abstracts from Sunday Nov. 12th. You can spot these on Twitter by looking for the (#ACRbest) hashtag.
Read Article
Majority of pts with axSpA had below avg aerobic capacity indicating high risk of morbidity.
Importance of supporting pts with axSpA to lead healthy lifestyle and improved aerobic capacity by exercise!
@RheumNow #ACR23 Abs#1395 https://t.co/SFAStGQaK0
Robert B Chao, MD ( View Tweet)
What if you have a first degree relative with ankylosing spondylitis?
100 pts w/o previous rheum dx w/ 1st degree AS relative
17% had MRI sacroiliitis
25% met classification criteria
14% dx with AS
@RheumNow #ACR23 Abs#1403 https://t.co/Z0juhRnLki
Robert B Chao, MD ( View Tweet)
15-year results from Abs #1389 at #ACR23 found only low back pain to be predictor of spinal radiographic progression in axSpA pts. Mean and median progression changes by mSASSS per year less in this cohort than previously documented. https://t.co/VKTEZWvH7f @rheumnow https://t.co/6sjPrcw2dD
Dr. Rachel Tate ( View Tweet)
Biologics are working for ankylosing spondylitis, even in reducing cardiovascular mortality!
Large retrospective study of over 4k pts over 20 years showed decrease in CV mortality from 34% in 1999 to 21% in 2020
@RheumNow #ACR23 Abs#1399
#ACRbest https://t.co/wKCIXHza0v
Robert B Chao, MD ( View Tweet)
Although general agreement that dz activity monitoring is important, implementation of AS/axSpA guideline recommendations is lacking. Guideline uptake & implementation should be considered in future updates of axSpA/AS tx recs. #ACR23 Abs #1385 https://t.co/RsyDppe3aR @rheumnow https://t.co/xxZ9pa77h9
Dr. Rachel Tate ( View Tweet)
In this updated pooled safety analysis from clinical trials of PsO, PsA & axSpA pts given SEC 150 &/or 300mg SC (ADeodhar et al)
⬆️freq AEs: nasopharyngitis & URTI
Low EAIRs/100pt yrs for IBD, malignancies & MACE
No new safety signals
Reassuring data.
#ACR23 ABST1436 @RheumNow https://t.co/guF0gC4hQM
sheila ( View Tweet)
In axSpA, the mean and median progression were 0.54 and 0.38 points in mSASSS per year respectively, lower than what has been reported in similar cohorts, LBP before diagnosis was a strong predictor of progression, Granados R Abst#1389 #ACR23 @RheumNow https://t.co/fvkOzhUG97 https://t.co/k18HxWswbs
Dr. Antoni Chan ( View Tweet)
Telemedicine tools with central evaluation of clinical and imaging (+/- MRI SIJs) information may be helpful in the diagnostic process for patients with suspected axSpA. This reduces the risk of overdiagnosis, Poddubnyy D, Abst#1392 #ACR23 @RheumNow https://t.co/kYEMdqmQF8 https://t.co/2lRg2byGjK
Dr. Antoni Chan ( View Tweet)
Pooled safety analysis of 48 phase II/III/IV trials on secukinumab for tx of PsO, PsA and axSpA
Well tolerated
No new long term safety signals
IBD, malginancy, MACE remain low
@RheumNow #ACR23 Abs#1436 https://t.co/6dzdO5Vpuc
Robert B Chao, MD ( View Tweet)
Using deep neural network for spinal inflammation in axial SpA, the area under the curve of the receiver operating characteristic (AUC-ROC) curve of the algorithm was 0.87±0.02, comparable with general radiologist Chan S et al Abst#1398 #ACR23 @RheumNow https://t.co/lrQRfc2RwN https://t.co/Fra8cDtQE5
Dr. Antoni Chan ( View Tweet)
#ACR23 Abs #0844 posterior element inflammation & facet joint ankylosis on MRI uncommon in r-axSpA patients. However, when FJ inflammation is present (vs w/o) the likelihood of developing facet joint ankylosis after 1 year is over 3 x higher. https://t.co/1Kln1pNH3p @rheumnow https://t.co/BatNTFfTG2
Dr. Rachel Tate ( View Tweet)
Validation is needed, but SPARTAN + add'l stakeholders developed the first draft SPARTAN recommendations for referral of adults with chronic back pain to a rheumatologist for evaluation of axSpA! Check out #ACR23 Abs #0841 https://t.co/ISv2lgHyka @rheumnow https://t.co/Qvy8LlzOw0
Dr. Rachel Tate ( View Tweet)
Sunday recap @RheumNow
Very interesting abstracts:
https://t.co/BX8bDSX1M3
1- Fecal calprotectin in SpA population.
2-SLE; high or low steroids? Rapid or slow taper?
3-Molecular biomarkers for PAH in SLE.
4-Repeating imaging in ? Chronic back pain?
And others …….
Nouf Al hemmadi ( View Tweet)
AS pts on UPA for 52 wks who were active or healthy weight/underweight at BL generally experienced greater decreases from BL in ASDAS-CRP and BASDAI vs pts who were inactive or overweight/obese. #ACR23 Abs #0540 https://t.co/OfgbmYUoAu @rheumno https://t.co/liptgbK2hJ
Dr. Rachel Tate ( View Tweet)
TNF AND IL17 was equally effective in Axial SpA!
#ACR23 #Reviewcourse https://t.co/oofQkvsJ3f
Nouf Al hemmadi ( View Tweet)
Takeaways from #ACR23 #ReviewCourse session on SpA Update: Radiographic and Non-Radiographic AS - Dr. Alexis Ogdie
1. Workup of inflammatory back pain: History, exam, CRP, HLA-B27, SI joint films, MRI pelvis (STIR images, no need for contrast). Response to NSAIDs not actually… https://t.co/M0W6UNsPxF https://t.co/7k3xl1RXZz
Paul Sufka, MD psufka ( View Tweet)
ABS0524:
⭐️Benefit of Certolizumab (CZP) over standard non-biologic tx in reducing acute anterior uveitis (AAU) flares among high risk pts w/ axSpA
➡️active dz, HLAB27+, 2 or more AAU flares
⭐️CZP reduced AAU flare rate by 87%
#ACR23 @RheumNow
#ACRBest https://t.co/rW0N18agMO
Meral K. El Ramahi, MD MeralElRamahiMD ( View Tweet)
ABS0538:
⭐️Characteristics of difficult-to-treat (D2T) axSpA pts:
➡️HLAB27(-)
➡️smokers
➡️shorter symptom duration
➡️more enthesitis
➡️IBD
➡️concomitant NSAID use
➡️Co-morbidities (HTN, HLD, fibro, depress/anxiety)
#ACR23 @RheumNow https://t.co/TqEVBeaJpb
Meral K. El Ramahi, MD MeralElRamahiMD ( View Tweet)
Yield of repeated assessments of SpA features in patients with CBP suspected of axSpA was modest for the increase of new definite axSpA diagnosis at 2y. Sacroilitis on MRI, good response to NSAIDs at BL most predictive of axSpA, ML Marques #ACR23 @RheumNow https://t.co/LQ5llML11M https://t.co/PYcCDypI7c
Dr. Antoni Chan ( View Tweet)
